EUCTR2015-001703-32-BE进行中（未招募）1 期
Phase III multicentric study evaluating the efficacy and safety of sirolimus in Vascular Anomalies that are refractory to standard care - VASE
Cliniques Universitaires Saint-Luc (CUSL)0 个研究点目标入组 250 人开始时间: 2015年10月12日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion is limited to children and adults from 3 months* to 70 years old:
- •* In Germany the inclusion is limited to adults only from 18 to 70 years old
- •-Patients with complex vascular anomalies that are refractory to standard care such as medical treatment, surgical resection and/or sclerotherapy/embolization (ineffective or accompanied by major complications)- – ref. page 57: Clinical parameters / diagnosis : Given the lack of response to conventional treatment ( compression stockings , anti- pain, low molecular weight heparin , sclerotherapy and / or surgery) (Dompmartin et al Phlebology 2010)
- •-Patients must have adequate bone marrow function: Hemoglobine> 10,0 g/dl, neutrophils >1500/mm³ and platelets > 100.000/mm³. Except for infants with hemangioendothelioma with risk of Kasabach-Merritt phenomenon (very low platelet count (lower than 80 000/mm3).
- •-Patients must have the following laboratory values:
- •oTotal serum bilirubin = 1.5 x ULN (or totally bilirubin =3 x ULN with direct bilirubin = 1.5 x ULN in patients with well documented Gilbert Syndrome)
- •oSerum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 x ULN
- •oSerum creatinine ?1.5 x ULN. If the serum creatinine is = 1.5 x ULN, then a 24-hour Creatinine Clearance must be conducted and the result must be = 60 mL/min.
- •-Absence of severe proteinuria
- •-Karnofsky > 50
- •-Parents or legal relatives have to be able to sign the informed consent
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 80
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 190
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Any of the following concurrent severe and/or uncontrolled medical conditions, which could compromise participation in the study or interfere with the study results:
- •Impaired cardiac function or clinically significant cardiac diseases, including unstable angina pectoris, ventricular arrhythmia, valvular disease with documented compromise in cardiac function, myocardial infarction within the last 6 months, documented by persistent elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LVEF function, history of documented congestive heart failure (New York Heart Association functional classification III-IV), documented cardiomyopathy, family history of congenital long or short QT, or known history of QT/QTc prolongation of Torsades de Pointes (TdP)
- •Impairment of Gastro-Intestinal (GI) function or GI disease that may significantly alter the absorption of sirolimus (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea = Grade 2, malabsorption syndrome, or small bowel resection)
- •Known hypersensitivity to drugs or metabolites from similar classes as study treatment.
- •Patient has other concurrent severe and /or uncontrolled medical condition that would,in the investigator’s judgment, contraindicated participation in the clinical study (e.g. acute or chronic pancreatitis, liver cirrhosis, active chronic hepatitis, severely impaired lung function with a spirometry = 50% of the normal predicted value and/or O2 saturation = 88% at rest, etc.)
- •Recent history of primary malignancy = 5 years, including history of non-melanoma skin cancer, but with with exception of carcinoma in situ of cervix.
- •Immunocompromised patients, including known seropositivity for HIV
- •Pregnant or lactating women
- •Prior treatment with PI3K and/or mTOR inhibitors
研究者
相似试验
进行中（未招募）
1 期
Sirolimus efficacy in the treatment of vascular anomaliesComplex vascular anomalies causing debilitating functional and esthetic impairment that are resistant to standard careMedDRA version: 18.1Level: HLTClassification code 10047047Term: Vascular anomalies congenital NECSystem Organ Class: 100000004850EUCTR2015-001703-32-FRCliniques Universitaires Saint-Luc (CUSL)250
进行中（未招募）
1 期
Sirolimus efficacy in the treatment of vascular anomaliesEUCTR2015-001703-32-DECliniques Universitaires Saint-Luc (CUSL)250
进行中（未招募）
1 期
Effects and treatment effect of sirolimus used against blood vessel deformities that are not suitable for surgical or other established treatment, or where established treatment has proven not to give satisfactory resultsEUCTR2015-001703-32-NOCliniques Universitaires Saint-Luc (CUSL)250
招募中
1 期
lcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitislcerative ColitisMedDRA version: 20.0Level: PTClassification code: 10009900Term: Colitis ulcerative Class: 100000004856CTIS2022-501788-41-00Abbvie Deutschland GmbH & Co. KG112
进行中（未招募）
1 期
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Crohn's DiseaseCTIS2023-509618-12-00AbbVie Deutschland GmbH & Co. KG137